An Open Label, Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy. - NA
Latest Information Update: 12 Nov 2019
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 05 Dec 2016 Status changed from not yet recruiting to completed.
- 08 Sep 2016 New trial record